Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label RUC-4 study in STEMI patients undergoing primary PCI
2019-004282-41Phase 2Completed
- Sponsor
- CeleCor Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalunfiban in myocardial infarction (MI), sponsored by CeleCor Therapeutics. Primary endpoint: TRAP-induced platelet aggregation inhibition at 240 minutes. Started Dec 2019; status: completed.
02
Drugs
zalunfiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2019-004282-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004282-41.